PDGFRA and cancer: Abnormal conditions such as hypoxia and glycosylation alter the function of several integrins, resulting in the activation of key signaling cascades upon interaction with pro-tumor secretory factors such as VEGF, FGF, and PDGFR2; therefore, integrins are a novel target for angiogenesis in cancer therapy [54].